open access

Vol 7, No 4 (2018)
REVIEW ARTICLES
Published online: 2018-09-11
Get Citation

Association of pentraxin 3 with atherosclerotic cardiovascular diseases — general knowledge in 2018

Artur Chodkowski, Katarzyna Nabrdalik, Hanna Kwiendacz, Janusz Gumprecht
DOI: 10.5603/DK.2018.0015
·
Clinical Diabetology 2018;7(4):203-206.

open access

Vol 7, No 4 (2018)
REVIEW ARTICLES
Published online: 2018-09-11

Abstract

Pentraxin 3 (PTX3), an acute phase protein, contrary to C-reactive protein (CRP), is produced locally, where the inflammation takes place, for example in the endothelium. It is not clearly known whether the inflammatory factors are the cause of atherosclerosis or only indicators of vascular inflammation. It is still not known what is the role of PTX in the natural history of atherosclerosis — protection or promotion. It was established that the elevated plasma concentration of PTX is related to the occurrence of cardiovascular events caused by atherosclerosis, including myocardial infarction (MI), decreased 3-months survival after MI, unstable angina or heart failure. On the other hand, PTX is suspected to play a protective role in the ischemic cardiac muscle. Therefore, if confirmed in trials, PTX3 could be administered during acute coronary syndrome. PTX3 might in the future become useful in assessing prognosis for patients with cardiovascular diseases and choosing the best therapeutic option for them.

Abstract

Pentraxin 3 (PTX3), an acute phase protein, contrary to C-reactive protein (CRP), is produced locally, where the inflammation takes place, for example in the endothelium. It is not clearly known whether the inflammatory factors are the cause of atherosclerosis or only indicators of vascular inflammation. It is still not known what is the role of PTX in the natural history of atherosclerosis — protection or promotion. It was established that the elevated plasma concentration of PTX is related to the occurrence of cardiovascular events caused by atherosclerosis, including myocardial infarction (MI), decreased 3-months survival after MI, unstable angina or heart failure. On the other hand, PTX is suspected to play a protective role in the ischemic cardiac muscle. Therefore, if confirmed in trials, PTX3 could be administered during acute coronary syndrome. PTX3 might in the future become useful in assessing prognosis for patients with cardiovascular diseases and choosing the best therapeutic option for them.
Get Citation

Keywords

pentraxin; atherosclerosis; cardiovascular diseases

About this article
Title

Association of pentraxin 3 with atherosclerotic cardiovascular diseases — general knowledge in 2018

Journal

Clinical Diabetology

Issue

Vol 7, No 4 (2018)

Pages

203-206

Published online

2018-09-11

DOI

10.5603/DK.2018.0015

Bibliographic record

Clinical Diabetology 2018;7(4):203-206.

Keywords

pentraxin
atherosclerosis
cardiovascular diseases

Authors

Artur Chodkowski
Katarzyna Nabrdalik
Hanna Kwiendacz
Janusz Gumprecht

References (34)
  1. Ross R. Atherosclerosis — An Inflammatory Disease. New England Journal of Medicine. 1999; 340(2): 115–126.
  2. Hansson GK. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circulation Research. 2002; 91(4): 281–291.
  3. Faxon DP, Fuster V, Libby P, et al. American Heart Association. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004; 109(21): 2617–2625.
  4. Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010; 28: 157–183.
  5. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006; 45(5): 326–330.
  6. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102(6): 636–641.
  7. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007; 27(1): 161–167.
  8. Latini R, Maggioni AP, Peri G, et al. Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110(16): 2349–2354.
  9. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008; 155(1): 75–81.
  10. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120(8): 699–708.
  11. Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23: 337–366.
  12. Gewurz H, Zhang XH, Lint T. Structure and function of the pentraxins. Current Opinion in Immunology. 1995; 7(1): 54–64.
  13. Basile A, Sica A, d'Aniello E, et al. Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem. 1997; 272(13): 8172–8178.
  14. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997; 272(52): 32817–32823.
  15. Doni A, Mantovani G, Porta C, et al. Cell-specific regulation of PTX3 by glucocorticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem. 2008; 283(44): 29983–29992.
  16. Casula M, Montecucco F, Bonaventura A, et al. Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017; 99: 1–12.
  17. Jaillon S, Peri G, Delneste Y, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007; 204(4): 793–804.
  18. Bottazzi B, Garlanda C, Salvatori G, et al. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006; 18(1): 10–15.
  19. Kunes P, Holubcova Z, Kolackova M, et al. Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012; 2012: 920517.
  20. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: An independent indicator of disease activity produced at sites of inflammation. Arthritis & Rheumatism. 2001; 44(12): 2841–2850, doi: 10.1002/1529-0131(200112)44:12<2841::aid-art472>3.0.co;2-6.
  21. Soeki T, Niki T, Kusunose K, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol. 2011; 58(2): 151–157.
  22. Savchenko As, Imamura M, Ohashi R, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008; 215(1): 48–55.
  23. Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002; 22(5): e10–e14.
  24. Tazaki R, Tanigawa J, Fujisaka T, et al. Plasma Pentraxin3 Level Is Associated With Plaque Vulnerability Assessed by Optical Coherence Tomography in Patients With Coronary Artery Disease. Int Heart J. 2016; 57(1): 18–24.
  25. Dubin R, Li Y, Ix JH, et al. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012; 163(2): 274–279.
  26. Jenny NS, Blumenthal RS, Kronmal RA, et al. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2014; 12(6): 999–1005.
  27. Kimura S, Inagaki H, Haraguchi Go, et al. Relationships of Elevated Systemic Pentraxin-3 Levels With High-Risk Coronary Plaque Components and Impaired Myocardial Perfusion After Percutaneous Coronary Intervention in Patients With ST-Elevation Acute Myocardial Infarction. Circulation Journal. 2014: 159–169.
  28. Guo R, Li Y, Wen J, et al. Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention. Cardiology. 2014; 129(3): 178–188.
  29. , et al ; 155: 75–81.
  30. Matsubara J, Sugiyama S, Nozaki T, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011; 57(7): 861–869.
  31. Napoleone E, di Santo A, Peri G, et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol. 2004; 76(1): 203–209.
  32. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120(8): 699–708.
  33. Slusher AL, Mischo AB, Acevedo EO. Pentraxin 3 is an anti-inflammatory protein associated with lipid-induced interleukin 10 in vitro. Cytokine. 2016; 86: 36–40.
  34. Camozzi M, Zacchigna S, Rusnati M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005; 25(9): 1837–1842.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl